Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,840.86 -1,319.71 (-2.12%) CMC Crypto 200
1,262.33 -95.67 (-7.04%)
Kronos Bio, Inc. (KRON)
| Previous close | 1.0500 |
| Open | 1.0800 |
| Bid | 0.9916 x 200 |
| Ask | 1.0200 x 200 |
| Day's range | 0.9614 - 1.0800 |
| 52-week range | 0.7310 - 2.2900 |
| Volume | |
| Avg. volume | 416,632 |
| Market cap | 60.395M |
| Beta (5Y monthly) | 1.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.9500 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.13 |
ZacksKronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
Kronos Bio (KRON) delivered earnings and revenue surprises of -16.28% and 68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireKronos Bio Reports First-Quarter 2024 Financial Results
— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new dose schedule remain on track to open in Q3 2024 — — KB-9558 remains on track with IND-enabling studies expected to complete in 2024 with first-in-human study anticipated to commence in the first half of 2025 — SAN MATEO, Calif. and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (
ZacksTravere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of -79.59% and 2.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
